The expression pattern is reported for the first time as a potential marker in MDS PLCB2, involved in inositol phosphate metabolism, has been narrowly linked to the poor prognosis in patients with hepatocellular carcinoma, lung cancer and mammary carcinoma.25 This evidence concerns the gene PLCB2 and hepatocellular carcinoma.